ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 2237
Assessment Of Wage and Salary Growth In Patients With Rheumatoid Arthritis (RA)
Abstract Number: 2238
Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With  persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Abstract Number: 2239
Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis
Abstract Number: 2240
Correlative Analysis Of Swollen Joints Between Clinical Examination and Musculoskeletal Ultrasound For Rheumatoid Arthritis
Abstract Number: 2241
Assessing Significant Flares In Rheumatoid Arthritis: Validity Of The Outcome Measures In Rheumatology Preliminary Flare Questions In The Canadian Early Arthritis Cohort
Abstract Number: 2242
Patient Versus Physician Joint Counts In Rheumatoid Arthritis Utilizing a Unique Self-Joint Examination Tool
Abstract Number: 2243
How Well Do The Three Generic Patient Reported Outcomes Measurement Information System Fatigue Instruments Perform In Rheumatoid Arthritis?
Abstract Number: 2244
Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a  Population Based Cohort
Abstract Number: 2245
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Abstract Number: 2246
Patients’ Assessment of the Disease Greatly Influences the Determination of Disease Activity and Remission in Rheumatoid Arthritis
Abstract Number: 2247
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Abstract Number: 2248
Difference Between The Two Versions Of Disease Activity Score Based On C-Reactive Protein and Erythrocyte Sedimentation Rate
Abstract Number: 2249
What Proportion Of Patients With Rheumatoid Arthritis Fail To Achieve Remission Based On The Patient Global? An Analysis From The Prospective, Observational Biologic Treatment Registry Across Canada
Abstract Number: 2250
What Is The Real World Relationship Between Patient-Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada
Abstract Number: 2251
Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a  Prospective, Observational Registry
Abstract Number: 2252
Assessment Of Rheumatoid Arthritis Disease Activity By Patients and Physicians: Do Physicians Detect Improvement Before The Patient Does?
Abstract Number: 2253
How Often Are Core Variables Reported To Calculate Common Disease Activity Scores Measured In Routine Care Of Rheumatoid Arthritis Patients?
Abstract Number: 2254
Complementary and Alternative Medicine in Rheumatoid Arthritis – Persistently High Use Over the Past Decade Despite Advent of Biologics
Abstract Number: 2255
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Abstract Number: 2256
Analysis of the Factors That Contribute to the Differences Between DAS28-ESR and DAS28-CRP
Abstract Number: 2257
Symptom Complexes At The Beginning Of Rheumatoid Arthritis: A Qualitative Exploration In At Risk Individuals and In New Patients Prior To Diagnosis
Abstract Number: 2258
Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials
Abstract Number: 2259
Does a Ratingen Score Of ≥ 3 At Disease Onset Define RA In ACR/EULAR 2010 Criteria Negative Patients?
Abstract Number: 2260
Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis
Abstract Number: 2261
Motivations For Inadequate Persistence With Disease Modifying Anti-Rheumatic Drugs In Early Rheumatoid Arthritis: The Patient’s Perspective
Abstract Number: 2262
Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Abstract Number: 2263
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Abstract Number: 2264
An Assay Panel Combining Anticitrullinated Peptide Autoantibodies and Rheumatoid Factor Isotypes Has High Yield In The Diagnosis Of Rheumatoid Arthritis
Abstract Number: 2265
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Abstract Number: 2266
Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study
Abstract Number: 2267
The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care
Abstract Number: 2268
Patient-Reported Outcome Measures For Rheumatoid Arthritis: Minimal Important Differences Review
Abstract Number: 2269
Patient Reported Pain: A Predictor Of Outcomes In Rheumatoid Arthritis From The Consortium Of Rheumatology Researchers Of North America Registry
Abstract Number: 2270
US Guided Treat-To-Target Approach In Early RA: Implications For Uncoupling Of Disease Activity and Structural Damage
Abstract Number: 2271
Dietary Sodium Increases The Risk For Rheumatoid Arthritis Among Smokers – Results From a Nested Case-Control Study
Abstract Number: 2272
Patient Survey Regarding Utility Of The Health Assessment Questionnaire Reveals An Unrecognized Aspect Of Disease Activity In Rheumatoid Arthritis: Consequences Of Physical Activity
Abstract Number: 2273
Patient Survey Challenges Conventional Notions Regarding Symptoms and Experiences Of People Living With Rheumatoid Arthritis
Abstract Number: 2274
Assessment Of The Diagnostic Accuracy Of Different Strategies For Health Fair Case-Finding For Undiagnosed Inflammatory Arthritis
Abstract Number: 2275
Responsiveness Of The Outcomes Measures In Rheumatology Clinical Trials Initiative’s Preliminary Flare Questions To Detect Flares Within Patients In The Canadian Early Arthritis Cohort
Abstract Number: 2276
Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort
Abstract Number: 2277
Midcarpal Joint Effusion Is As Common As Radiocarpal Joint Effusion In Swollen Wrists Of Patients With Rheumatoid Arthritis
Abstract Number: 2278
Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers:  Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Abstract Number: 2279
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
Abstract Number: 2280
Stiffness From The Perspective Of People Living With Rheumatoid Arthritis
Abstract Number: 2281
An Analysis Of Highly Discordant Erythrocyte Sedimentation and C Reactive Protein Levels In Rheumatoid Arthritis
Abstract Number: 2282
Performance Of The 2010 ACR/EULAR Classification Criteria For Rheumatoid Arthritis In a Group Of Elderly Onset Patients
Abstract Number: 2283
The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes
Abstract Number: 2284
How Well Do Generic Patient Reported Outcomes Measurement Information System Instruments Capture Health Status In Rheumatoid Arthritis?
Abstract Number: 2285
Correlation Of Individual Health Assessment Questionnaire (HAQ) Questions With Outcome Measures In Rheumatoid Arthritis: Implications For Instrument Reduction
Abstract Number: 2286
Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Abstract Number: 2287
What Is The Internal Consistency Of The Disease Activity Score (DAS)-28 In Rheumatoid Arthritis Patients Treated In a Real–World Setting?
Abstract Number: 2288
Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients
Abstract Number: 2289
Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis
Abstract Number: 2290
Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis
Abstract Number: 2291
Only Rheumatoid Factor-Positive Subset Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive
Abstract Number: 2292
Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative
Abstract Number: 2293
Anti-Citrullinated Peptide/Protein Antibody Specificities and Subclinical Synovitis In Palindromic Rheumatism: Towards a Better Understanding Of The Relationship With Rheumatoid Arthritis
Abstract Number: 2294
The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis  From The Norwegian Very Early Arthritis Clinic
Abstract Number: 2295
Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up
Abstract Number: 2296
Are SDAI50 and DAS28 Response Measures Comparable In Early Rheumatoid Arthritis Patients?
Abstract Number: 2297
Evaluating Depression Questionnaires In German Rheumatoid Arthritis Patients – Preliminary Results From a Validation Study
Abstract Number: 2298
Upper-Half Serum IgA (20+ TU/ml) and IgM (10+ IU/ml) Levels Significantly Predicted The Long-Term (mean 12 yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values
Abstract Number: 2299
Disease Activity Scoring: Comparing Patient and Physician Global Assessment Of Disease Activity In Rhumatoid Arthritis Patients Starting a First Biologic Agent
Abstract Number: 2300
Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting
Abstract Number: 2301
T Cell Proliferative Response To Type II Collagen In Patients With Rheumatoid Arthritis
Abstract Number: 2302
Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis
Abstract Number: 2303
Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis
Abstract Number: 2304
Follow-Up Of Patients With Preclinical Rheumatoid Arthritis – Results Of a Telephone Survey
Abstract Number: 2305
Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences